CRL / Charles River Laboratories International, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2025 RESULTS – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance –

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2025 RESULTS – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – WILMINGTON, MA, August 6, 2025 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 28, 2025 OR ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Amendment to the Amended and Restated Employment Agreement by and between James C. Foster and Charles River International, Inc., dated May 20, 2025

Exhibit 10.1 AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO.1 (this “Amendment”) to the Amended and Restated Employment Agreement by and between James C. Foster (the “Executive”) and Charles River Laboratories International, Inc., a Delaware corporation (the “Company” and, hereinafter collectively referred to as “parties”), dated as of May 18, 2021 (the “Employment Agreement”), is entere

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 251 Ballardvale Street Wilm

CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2025 RESULTS – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Mil

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2025 RESULTS – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – WILMINGTON, MA, May 7, 2025 – Charles River Laboratories International, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio

Cooperation Agreement, by and among the Company and Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P., dated as of May 6, 2025

Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “Agreement”), dated as of May 6, 2025 (the “Effective Date”), is made by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership, and Elliott International, L.P., a Cayman Islands limited partnership (each, an “Elliott Party” and, collectively, the “Ell

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 29, 2025 OR ☐ TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 29, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Com

Exhibit 99.1 NEWS RELEASE Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company’s Business – – Enters into Cooperation Agreement with Elliott Investment Manageme

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 20, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

Charles River Executive Separation Plan dated December 05, 2024

Exhibit 10.7 CHARLES RIVER EXECUTIVE SEPARATION PLAN (Last Revised on December 05, 2024) 1.1Background 1.2Purpose: The purpose of the Charles River Executive Separation Plan is to establish an equitable measure of compensation for employees of Charles River Laboratories International, Inc. and/or its subsidiaries (“the Company”) designated with a title of Vice President or higher (“Executives”) in

Charles River Laboratories amended and restated Deferred Compensation Plan, as amended

Exhibit 10.13 AMENDED AND RESTATED DEFERRED COMPENSATION PLAN DOCUMENT February 8, 2006 (Amended December 2, 2008, July 20, 2011 April 22, 2021 and January 30, 2025) ARTICLE 1. INTRODUCTION Charles River Laboratories hereby establishes the Charles River Laboratories Deferred Compensation Plan effective as of January 1, 2006. The Company has established the Plan to attract, retain and motivate cert

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN

CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS AND PROVIDES 2025 GUIDANCE – Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS AND PROVIDES 2025 GUIDANCE – Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Pro

Subsidiaries of Charles River Laboratories International, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 19, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 14, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

Tenth Amended and Restated Credit Agreement, dated as of December 13, 2024, among Charles River Laboratories International, Inc., the Subsidiary Borrowers party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A. as administrative agent, and the other agents party thereto.

Exhibit 10.1 TENTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of December 13, 2024 among CHARLES RIVER LABORATORIES INTERNATIONAL, INC., The Subsidiary Borrowers Party Hereto, The Lenders Party Hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent BANK OF AMERICA, N.A., CITIBANK, N.A., CITIZENS BANK, N.A., Td SECURITIES (usA) LLC, U.S. BANK NATIONAL ASSOCIATION and WELLS FARGO BANK, N.A.

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of

CRL / Charles River Laboratories International, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Charles River Laboratories International, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 159864107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Charles River Laboratories International, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with th

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 28, 2024 OR ☐ TRANSITION R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

CHARLES RIVER LABORATORIES ANNOUNCES THIRD-QUARTER 2024 RESULTS – Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance –

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES THIRD-QUARTER 2024 RESULTS – Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance – WILMINGTON, MA, November 6, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 202

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpora

CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2024 RESULTS – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board Approves New Stock Repurchase Authorizat

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2024 RESULTS – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board Approves New Stock Repurchase Authorization of $1.0 Billion – – Revises 2024 Guidance – WILMINGTON, MA, August 7, 2024 – Charles River Laboratories International, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 29, 2024 OR ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 251 Ballardvale Street Wilm

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio

Form of Subordinated Debt Indenture between the Registrant and U.S. Bank Trust Company, National Association.

Exhibit 4.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee Subordinated Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 6 Section 1.04. Rules

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 30, 2024 OR ☐ TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Statement of Eligibility of U.S. Bank Trust Company, National Association on Form T-1 for Senior Debt Indenture.

Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) [] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S.

Form of Senior Debt Indenture between the Registrant and U.S. Bank Trust Company, National Association.

Exhibit 4.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee Senior Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Con

Press release dated May 9, 2024

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2024 RESULTS – First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – WILMINGTON, MA, May 9, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. Fo

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Charles River Laboratories International, Inc.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

Sixth Amended and Restated By-laws.

Exhibit 3.2 SIXTH AMENDED AND RESTATED BY-LAWS OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SIXTH AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS ARTICLE I - Stockholders 3 1.1 Place of Meetings 3 1.2 Annual Meeting 3 1.3 Special Meetings 3 1.4 Notice of Meeting 3 1.5 Voting List 4 1.6 Quorum 4 1.7 Adjournments 4 1.8 Voting and Proxies 4 1.9 Proxy Representation 4 1.10 Action at Meeting; Major

Statement of Eligibility of U.S. Bank Trust Company, National Association on Form T-1 for Subordinated Debt Indenture.

Exhibit 25.2 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) [] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Charles River Laboratories International, Inc. Amended and Restated 2018 Incentive Plan, dated March 20, 2018, as amended November 21, 2023

Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED 2018 INCENTIVE PLAN Originally adopted by the Board of Directors On March 20, 2018 Approved at Annual Meeting of Shareholders On May 8, 2018 Amended by the Board of Directors On March 14, 2020 Amendment and Restatement Approved at Annual Meeting of Shareholders On May 6, 2020 Amended by the Administrator (the Compensa

Subsidiaries of Charles River Laboratories International, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN

Financial Statement Compensation Recoupment Policy

EXHIBIT 97 GLOBAL CORPORATE POLICY Doc #: GLBL-POL-00093 Rev #: 1 Effective Date: 2023/10/23 Policy Sponsor: Corporate Legal Title: Financial Statement Compensation Recoupment Policy PURPOSE This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under U.

Insider Trading Policy

EXHIBIT 19 GLOBAL CORPORATE POLICY Doc #: GLBL-POL-00060 Rev #: 3 Effective Date: 19/Jan/2024 Policy Sponsor: Corporate Legal Title: Insider Trading Policy PURPOSE It is the policy of Charles River Laboratories International, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe

Charles River Laboratories International, Inc. Form of Restricted Stock Unit granted under the 2018 Incentive Plan

Exhibit 10.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this “Award Document”), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the “Plan”). Pursuant to Section 4(c) of the Plan, you have been

Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Exhibit 99.1 Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024

CRL / Charles River Laboratories International, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0582-charlesriverlaborator.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Charles River Laboratories International Inc Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpor

251 Ballardvale Street, Wilmington, Massachusetts 01887

VIA EDGAR November 21, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology Attn: Kristin Lochhead, Senior Staff Accountant Brian Cascio, Accounting Branch Chief Re: Charles River Laboratories International, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Form 8-K dated November 8, 2023 File No. 001-15943 Members of the Staff: Charles River L

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

Charles River Laboratories Announces Third-Quarter 2023 Results

Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2023 Results – Third-Quarter Revenue of $1.03 Billion – – Third-Quarter GAAP Earnings per Share of $1.69 and Non-GAAP Earnings per Share of $2.72 – – Updates 2023 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-November 8, 2023-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED July 1, 2023 OR ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED July 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER L

Charles River Laboratories Announces Second-Quarter 2023 Results

Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2023 Results – Second-Quarter Revenue of $1.06 Billion – – Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 – – Updates 2023 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-August 9, 2023-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 251 Ballardvale Street Wilm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati

Second Amendment to the Ninth Amended and Restated Credit Agreement, dated March 30, 2023, among Charles River Laboratories International, Inc., the Subsidiary Borrowers party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and the other agents party thereto

Exhibit 10.1 Execution Version SECOND AMENDMENT TO THE NINTH AMENDED AND RESTATED CREDIT AGREEMENT SECOND AMENDMENT (this “Agreement”) dated as of March 30, 2023 relating to the Ninth Amended and Restated Credit Agreement dated as of April 21, 2021 (as amended by the First Amendment, dated as of February 28, 2022 and as further heretofore amended or modified, the “Credit Agreement” and as amended

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED April 1, 2023 OR ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED April 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (I

Charles River Laboratories Announces First-Quarter 2023 Results

Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2023 Results – First-Quarter Revenue of $1.03 Billion – – First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 – – Updates 2023 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-May 11, 2023-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.                 )

DEFA14A 1 dp193107defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.                 ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Subsidiaries of Charles River Laboratories International, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance

Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48 and Non-GAAP Earnings per Share of $11.12 – – Provides 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe

CRL / Charles River Laboratories Intl. Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Charles River Laboratories International Inc. Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to whic

EX-24

EX-24 2 exhibit24.txt Exhibit 24 POWER OF ATTORNEY Effective as of the date hereof, the undersigned does hereby appoint Stephanie J. Brown, with full power of substitution, as the true and lawful attorney of the undersigned, with full power and authority to execute such documents and to make such regulatory or other filings and amendments thereto as shall from time to time be required pursuant to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

Charles River Laboratories Announces Third-Quarter 2022 Results

Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2022 Results ? Third-Quarter Revenue of $989.2 Million ? ? Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 ? ? Narrows 2022 Revenue Growth and Earnings Per Share Guidance ? ? Announces Planned Divestiture of Avian Vaccine Business ? WILMINGTON, Mass.-(BUSINESS WIRE)-November 2, 2022-Charles Rive

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 24, 2022 OR ☐ TRANSITION R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 24, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 25, 2022 OR ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 25, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Charles River Laboratories Announces Second-Quarter 2022 Results

Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2022 Results – Second-Quarter Revenue of $973.1 Million – – Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 – – Reduces 2022 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-August 3, 2022-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 8, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter)

SD 1 dp173953sd.htm FORM SD OMB APPROVAL OMB Number: 3235-0697 Expires: July 31, 2024 Estimated average burden hours per response...477.89 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati

Employment Offer Letter between Charles River Laboratories, Inc. and Flavia Pease, dated as of March 4, 2022

Exhibit 10.1 March 4, 2022 Flavia Pease [***] Subject: Employment Offer Letter Dear Flavia, Charles River Laboratories, Inc. (?Charles River?) is pleased to offer you the position of Executive Vice President, Chief Financial Officer, beginning on a mutually agreed upon date in 2022. In this role, you will report directly to me, and will work remotely from your home in [***]. This full-time positio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 26, 2022 OR ☐ TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 26, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Charles River Laboratories Announces First-Quarter 2022 Results

Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2022 Results ? First-Quarter Revenue of $913.9 Million ? ? First-Quarter GAAP Earnings per Share of $1.81 and Non-GAAP Earnings per Share of $2.75 ? ? Updates 2022 Guidance ? WILMINGTON, Mass.-(BUSINESS WIRE)-May 4, 2022-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2022

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (IR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 28, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

Subsidiaries of Charles River Laboratories International, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint?Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results

Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results ? Fourth-Quarter Revenue of $905.1 Million and Full-Year Revenue of $3.54 Billion ? ? Fourth-Quarter GAAP Earnings per Share of $2.67 and Non-GAAP Earnings per Share of $2.49 ? ? Full-Year GAAP Earnings per Share of $7.60 and Non-GAAP Earnings per Share of $10.32 ? ? Reaffirms 2022 Guidance ? WILMINGTON, Ma

Agreement between David Ross Smith and Charles River Discovery Research Services UK Limited dated February 15, 2022

Exhibit 10.18 Private & Confidential Mr D.R. Smith [***] 14 February 2022 Dear David, Compensation changes & Succession terms The following has been decided in respect of your personal compensation: A.Your basic annual salary shall increase to ?479,981 with effect from 1st of April 2022. B.In accordance with, and as per, clause 5.3 of your service agreement dated 1 December 2020 (?Service Agreemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 25, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 25, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN

CRL / Charles River Laboratories Intl. Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Charles River Laboratories International Inc. Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to whic

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc. JP Morgan 40th Annual Healthcare Conference James C. Foster Chairman, President & Chief Executive Officer Charles River Laboratories January 11, 2022 EVERY STEP OF THE WAY Sa

aex991xcrljpm2022present EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. Performance Share Unit Award dated December 25, 2021 granted to Joseph W. LaPlume

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT (the ?Award Agreement?) This Performance Share Unit Award (the ?Award?) is granted as of December 25, 2021 by Charles River Laboratories International, Inc. (the ?Company?) to Joseph W. LaPlume (the ?Participant?) on the terms and conditions as set forth in this Award Agreement and in the 2018

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 22, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

Charles River Laboratories International, Inc. Restricted Stock Unit Award dated December 25, 2021 granted to Joseph W. LaPlume

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this ?Award Document?), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the ?Plan?). Pursuant to Section 4(c) of the Plan, you have been granted rest

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

Sixth Amended and Restated By-Laws of Charles River Laboratories International, Inc.

Exhibit 3.1 SIXTH AMENDED AND RESTATED BY-LAWS OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SIXTH AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS ARTICLE I - Stockholders 3 1.1 Place of Meetings 3 1.2 Annual Meeting 3 1.3 Special Meetings 3 1.4 Notice of Meeting 3 1.5 Voting List 4 1.6 Quorum 4 1.7 Adjournments 4 1.8 Voting and Proxies 4 1.9 Proxy Representation 4 1.10 Action at Meeting; Major

CHARLES RIVER LABORATORIES PROMOTES BIRGIT GIRSHICK TO CHIEF OPERATING OFFICER

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES PROMOTES BIRGIT GIRSHICK TO CHIEF OPERATING OFFICER WILMINGTON, MA, November 11, 2021 ? Charles River Laboratories International, Inc. (NYSE: CRL) today announced that Birgit Girshick has been promoted to the position of Chief Operating Officer, effective immediately. In her most recent role as Corporate Executive Vice President, Ms. Girshick ha

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of i

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 25, 2021 OR ☐ TRANSITION R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 25, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number

Charles River Laboratories Announces Third-Quarter 2021 Results

Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2021 Results ? Third-Quarter Revenue of $895.9 Million ? ? Third-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.70 ? ? Updates 2021 Guidance ? WILMINGTON, Mass.-(BUSINESS WIRE)-November 3, 2021-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number)

Charles River Laboratories Announces Second-Quarter 2021 Results

Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2021 Results Second-Quarter Revenue of $914.6 Million Second-Quarter GAAP Earnings per Share of $1.72 and Non-GAAP Earnings per Share of $2.61 Increases 2021 Guidance WILMINGTON, Mass.-(BUSINESS WIRE)-August 4, 2021-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2021. F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 26, 2021 OR ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 26, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter)

SD 1 dp151959sd.htm FORM SD OMB APPROVAL OMB Number: 3235-0697 Expires: March 31, 2023 Estimated average burden hours per response.480.61 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or o

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Exhibit 99.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is hereby entered into as of May 18, 2021 by and between Charles River Laboratories International, Inc., a Delaware corporation (the ?Company?), and James C. Foster, an individual (the ?Executive?) (hereinafter collectively referred

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of Inco

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio

Statement of Eligibility of U.S. Bank National Association on Form T-1 for Senior Debt Indenture.

EX-25.1 6 dp150175ex2501.htm EXHIBIT 25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its cha

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 27, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Statement of Eligibility of U.S. Bank National Association on Form T-1 for Subordinated Debt Indenture.

Exhibit 25.2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identific

Charles River Laboratories amended and restated Deferred Compensation Plan, as amended

Exhibit 10.3 AMENDED AND RESTATED DEFERRED COMPENSATION PLAN DOCUMENT February 8, 2006 (Amended December 2, 2008, July 20, 2011 and April 22, 2021) ARTICLE 1.Introduction Charles River Laboratories hereby establishes the Charles River Laboratories Deferred Compensation Plan effective as of January 1, 2006. The Company has established the Plan to attract, retain and motivate certain of its key empl

Form of Senior Debt Indenture between the Registrant and U.S. Bank National Association.

Exhibit 4.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK NATIONAL ASSOCIATION as Trustee Senior Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 ART

- FORM S-3ASR

As filed with the Securities and Exchange Commission on May 4, 2021 Registration No.

Form of Subordinated Debt Indenture between the Registrant and U.S. Bank National Association.

Exhibit 4.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK NATIONAL ASSOCIATION as Trustee Subordinated Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 6 Section 1.04. Rules of Construction

Executive Incentive Compensation Program effective January 1, 2021

Exhibit 10.2 PURPOSE The Executive Incentive Compensation Program (?EICP? or the ?Program?) of Charles River Laboratories, Inc. (the ?Company?) is designed to focus employees at the Vice President (?VP?) level and higher on the achievement of organizational, financial and operational goals that have been identified as important for the success of the Company. The Program is also intended to attrac

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (IR

Charles River Laboratories Announces First-Quarter 2021 Results

Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2021 Results ? First-Quarter Revenue of $824.6 Million ? ? First-Quarter GAAP Earnings per Share of $1.20 and Non-GAAP Earnings per Share of $2.53 ? ? Updates 2021 Guidance ? WILMINGTON, Mass.-(BUSINESS WIRE)-May 4, 2021-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2021

Agreement between David Ross Smith and Charles River Discovery Research Services UK Limited effective December 1, 2020

Exhibit 10.1 Private & Confidential Charles River Discovery Research Services Uk Limited (1) & David Ross Smith (2) SERVICE AGREEMENT THIS AGREEMENT IS A DEED and is made on 2020 BETWEEN: (1)Charles River Discovery Research Services UK Limited (Registered Company Number 04622227) whose registered office is at Robinson Building Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 21, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of In

Ninth Amended and Restated Credit Agreement, dated as of April 21, 2021, among Charles River Laboratories International, Inc., the Subsidiary Borrowers party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A. as administrative agent, and the other agents party thereto.

EX-10.1 2 dp149793ex1001.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version NINTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 21, 2021 among CHARLES RIVER LABORATORIES INTERNATIONAL, INC., The Subsidiary Borrowers Party Hereto, The Lenders Party Hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent BANK OF AMERICA, N.A., CITIBANK, N.A., MUFG BANK, LTD., TD BANK, N.A. and WELLS FARGO

CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF COGNATE BIOSERVICES

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF COGNATE BIOSERVICES WILMINGTON, MA, March 29, 2021 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million, subject to customary closing adjustments. Cognate BioServices is a pre

Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of inco

- DEF 14A

QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 23, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of In

CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING WILMINGTON, Mass., March 23, 2021?Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 3.750% senior notes due 2029 (the ?2029 notes?) and $500 million in aggregate principal a

Indenture, dated as of March 23, 2021, between the Company and U.S. Bank National Association, as trustee.

Exhibit 4.1 Execution Version Charles River Laboratories International, Inc. INDENTURE Dated as of March 23, 2021 U.S. Bank National Association as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.1. Definitions 1 SECTION 1.2. Concerning the Trust Indenture Act 6 SECTION 1.3. Rules of Construction 6 ARTICLE II THE SECURITIES 7 SECTION 2.1. Issuable in

First Supplemental Indenture, dated as of March 23, 2021, by and among the Company, the Guarantors and U.S. Bank National Association, as trustee.

Exhibit 4.2 Execution Version CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as Issuer EACH OF THE GUARANTORS PARTY HERETO as Guarantors U.S. BANK NATIONAL ASSOCIATION as Trustee First Supplemental Indenture Dated as of March 23, 2021 to the Indenture dated as of March 23, 2021 3.750% Senior Notes due 2029 4.000% Senior Notes due 2031 TABLE OF CONTENTS PAGE ARTICLE 1. DEFINITIONS AND OTHER PROVISI

CHARLES RIVER LABORATORIES PRICES $1 BILLION OF SENIOR NOTES

Exhibit 99.2 NEWS RELEASE CHARLES RIVER LABORATORIES PRICES $1 BILLION OF SENIOR NOTES WILMINGTON, Mass., March 9, 2021 ? Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it priced its private offering (the ?offering?) of $500 million in aggregate principal amount of 3.750% senior notes due 2029 (the ?2029 notes?) and $500 million in aggregate principal amount of 4.0

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of Inc

CHARLES RIVER LABORATORIES ANNOUNCES PLANNED OFFERING OF $1 BILLION OF SENIOR NOTES

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES PLANNED OFFERING OF $1 BILLION OF SENIOR NOTES WILMINGTON, Mass., March 8, 2021 ? Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $1 billion aggregate principal amount of senior notes due 2029 and 2031 (the ?notes?) in an unregistered offering, subject to market conditions. Charles Ri

Agreement and Plan of Merger, dated as of February 17, 2021, by and among Charles River Laboratories International, Inc., Memphis Merger Sub, Inc., Cognate BioServices, Inc. and Mercury Fund 2 Holdco LLC, solely in its capacity as the initial representative of the Company Shareholders

Exhibit 2.1 agreement and plan of merger BY AND AMONG CHARLES RIVER LABORATORIES INTERNATIONAL, INC., MEMPHIS MERGER SUB, INC., cognate bioservices, inc. AND THE SELLERS’ REPRESENTATIVE named HEREIN DATED AS OF February 17, 2021 TABLE OF CONTENTS Page Article 1 MERGER 2 1.1 Rollover and Merger 2 1.2 The Closing and the Effective Time 2 1.3 Effect of the Merger 2 1.4 Organizational Documents of the

Subsidiaries of Charles River Laboratories International, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint?Constant S.A. Quebec, Canada 4 Charles River Holdings LLC Delaware 5 Ballardvale C.V. Netherlands 6 Charles River Nederland B.V. Netherlands 7 Charles River Laboratories Holding SAS France 8 Charles Rive

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 26, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABO

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 17, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 17, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance

Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance ? Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion ? ? Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 ? ? Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per Share of $8.13 ? ? Provides 2021

CHARLES RIVER LABORATORIES TO ACQUIRE COGNATE BIOSERVICES TO CREATE A PREMIER SCIENTIFIC PARTNER FOR CELL AND GENE THERAPY DEVELOPMENT – Significantly Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector – –

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES TO ACQUIRE COGNATE BIOSERVICES TO CREATE A PREMIER SCIENTIFIC PARTNER FOR CELL AND GENE THERAPY DEVELOPMENT ? Significantly Expands Charles River?s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector ? ? Combines Cognate?s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery

Form of Support Agreement

Exhibit 10.1 SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is dated as of February 17, 2021, by and among Charles River Laboratories International, Inc., a Delaware corporation (?Buyer?), and each of the equityholder(s) of Cognate BioServices, Inc., a Delaware corporation (the ?Company?) listed on the signature pages hereto (each, a ?Holder?). For purposes of this Agreement, Buyer an

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Charles River Laboratories International Inc. Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to whic

LETTER

United States securities and exchange commission logo December 31, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc.

-

United States securities and exchange commission logo December 31, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc.

-

December 17, 2020 BY EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.

LETTER

United States securities and exchange commission logo December 7, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc.

-

United States securities and exchange commission logo December 7, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

Agreement between David Smith and Charles River Laboratories, Inc. effective October 26, 2020

Exhibit 10.1 PERSONAL AND CONFIDENTIAL October 26, 2020 David Smith c/o Charles River Laboratories, Inc. 251 Ballardvale Street Wilmington, MA 01887 David: The purpose of this letter is to summarize the transfer of your employment from Wilmington, MA, U.S. (your “origin location”) to Cambridge, England, in the Charles River Discovery Research Services UK LTD entity (your “destination location”), e

- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 29, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number

Charles River Laboratories Announces Third-Quarter 2020 Results

Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2020 Results – Third-Quarter Revenue of $743.3 Million – – Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 – – Increases 2020 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-October 29, 2020-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

Agreement between David Smith and Charles River Laboratories, Inc. effective October 26, 2020

Exhibit 10.1 PERSONAL AND CONFIDENTIAL October 26, 2020 David Smith Apartment 31 8 Simpson Loan Edinburgh EH3 9GS David: The purpose of this letter is to summarize the transfer of your employment from Wilmington, MA, U.S. (your “origin location”) to Cambridge, England, in the Charles River Discovery Research Services UK LTD entity (your “destination location”), effective as of December 1, 2020. As

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

Charles River Laboratories International, Inc. Form of Non-Qualified Stock Option granted under the 2018 Incentive Plan

Exhibit 10.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Non-Qualified Stock Option Granted Under 2018 Incentive Plan The Company's most recent Annual Report to Shareholders containing the Company’s audited financial statements for the last three years and its Annual Report on Form 10-K is available on the Company's website at http://www.criver.com. You are urged to review those documents befor

Charles River Laboratories International, Inc. Form of Performance Share Unit granted under the 2018 Incentive Plan

Exhibit 10.3 FORM OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”) This Performance Share Unit Award (the “Award”) is granted as of May 29, 2020 by Charles River Laboratories International, Inc. (the “Company”) to «FN» «LN» (the “Participant”) on the terms and conditions as set forth in this Award Agreement and in

Charles River Laboratories Announces Second-Quarter 2020 Results

Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2020 Results – Second-Quarter Revenue of $682.6 Million – – Second-Quarter GAAP Earnings per Share of $1.34 and Non-GAAP Earnings per Share of $1.58 – – Increases 2020 Guidance – – Announces Proposed Acquisition of Cellero in the High-Growth Cell Therapy Market – WILMINGTON, Mass.-(BUSINESS WIRE)-August 5, 2020-Charles River Laborato

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 5, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number)

Charles River Laboratories International, Inc. Form of Restricted Stock Unit granted under the 2018 Incentive Plan

Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this “Award Document”), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the “Plan”). Pursuant to Section 4(c) of the Plan, you have been

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 27, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

- SD

OMB APPROVAL OMB Number: 3235-0697 Expires: March 31, 2023 Estimated average burden hours per response.

- S-8

As filed with the Securities and Exchange Commission on May 21, 2020 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio

Charles River Laboratories International, Inc. Amended and Restated 2018 Incentive Plan, dated March 20, 2018, as amended and restated May 6, 2020

Exhibit 10.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED 2018 INCENTIVE PLAN Originally adopted by the Board of Directors On March 20, 2018 Approved at Annual Meeting of Shareholders On May 8, 2018 Amended by the Board of Directors On March 14, 2020 Amendment and Restatement Approved at Annual Meeting of Shareholders On May 6, 2020 1.ADMINISTRATION Subject to the express pr

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (IR

Charles River Laboratories Announces First-Quarter 2020 Results

Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2020 Results – First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $1.84 – – Revises 2020 Guidance Due to COVID-19 Impact – WILMINGTON, Mass.-(BUSINESS WIRE)-May 7, 2020-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for th

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 28, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

CRL / Charles River Laboratories International, Inc. DEF 14A - - DEF 14A

QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

CRL / Charles River Laboratories International, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Charles River Laboratories International Inc Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABO

Description of Securities

Exhibit 4.2 DESCRIPTION OF SECURITIES The following description is based upon our second amended and restated certificate of incorporation, our fifth amended and restated by-laws and applicable provisions of law. We have summarized certain portions of the second amended and restated certificate of incorporation and third amended and restated by-laws below. The summary is not complete. The second a

Subsidiaries of Charles River Laboratories International, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Holdings LLC Delaware 5 Ballardvale C.V. Netherlands 6 Charles River Nederland B.V. Netherlands 7 Charles River Laboratories Holding SAS France 8 Charles Rive

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance

Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance – Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.61 and Non-GAAP Earnings per Share of $2.01 – – Full-Year GAAP Earnings per Share of $5.07 and Non-GAAP Earnings per Share of $6.73 – – Provides 2020

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 11, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe

Charles River Laboratories Announces Third-Quarter 2019 Results

Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2019 Results – Third-Quarter Revenue of $668.0 Million – – Third-Quarter GAAP Earnings per Share of $1.46 and Non-GAAP Earnings per Share of $1.69 – – Updates 2019 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-November 6, 2019-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number

Charles River Laboratories International, Inc. Second Amendment dated September 25, 2019 relating to the Eighth Amended and Restated Credit Agreement dated March 26, 2018

Exhibit 10.2 SECOND AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CREDIT AGREEMENT SECOND AMENDMENT (this “Amendment”) dated as of September 25, 2019 relating to the Eighth Amended and Restated Credit Agreement dated as of March 26, 2018 (as heretofore amended or modified, the “Credit Agreement”) among Charles River Laboratories International, Inc. (the “Parent Borrower”), the Subsidiary Borrowers

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

Agreement between David Johst and Charles River Laboratories, Inc. effective July 26, 2019

Exhibit 10.1 AGREEMENT This Agreement (the “Agreement”), with an effective date of July 26, 2019, is entered into by Charles River Laboratories, Inc., with its principal place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (the “Company”) and Mr. David P. Johst, an individual residing at 7 Meadow View Lane, Andover, MA 01810 (the “Employee”). The Employee and the Company re

Charles River Laboratories International, Inc. Third Amendment dated November 4, 2019 relating to the Eighth Amended and Restated Credit Agreement dated March 26, 2018

Exhibit 10.3 THIRD AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CREDIT AGREEMENT THIRD AMENDMENT (this “Amendment”) dated as of November 4, 2019 relating to the Eighth Amended and Restated Credit Agreement dated as of March 26, 2018 (as heretofore amended or modified, the “Credit Agreement”) among Charles River Laboratories International, Inc. (the “Parent Borrower”), the Subsidiary Borrowers part

Charles River Laboratories International, Inc. Second Supplemental Indenture, dates as of October 23, 2019, to the Indenture dated as of April 3, 2018

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as Issuer EACH OF THE GUARANTORS PARTY HERETO as Guarantors MUFG UNION BANK, N.A. as Trustee Second Supplemental Indenture Dated as of October 23, 2019 to the Indenture dated as of April 3, 2018 4.250% Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 Section 1.01 Scope of Supplemental In

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 23, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING WILMINGTON, MA, October 23, 2019 - Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 4.25% senior notes due 2028 (the “notes”) in an unregistered offering. The notes have no

Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 21, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

Excerpts from the Preliminary Offering Memorandum dated October 21, 2019

Exhibit 99.1 Excerpts from the Preliminary Offering Memorandum dated October 21, 2019 Recent developments - Preliminary and unaudited estimates of the Company’s selected third quarter 2019 results Set forth below are preliminary estimates of unaudited selected financial information for the three months ended September 28, 2019 and actual unaudited financial results for the three months ended Septe

CHARLES RIVER LABORATORIES ANNOUNCES OFFERING OF $500 MILLION OF SENIOR NOTES

Exhibit 99.2 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES OFFERING OF $500 MILLION OF SENIOR NOTES WILMINGTON, MA, October 21, 2019 - Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate principal amount of senior notes due 2028 (the “notes”) in an unregistered offering, subject to market conditions. Charles River intend

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpor

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 30, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporat

Charles River Laboratories Announces Second-Quarter 2019 Results

Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2019 Results – Second-Quarter Revenue of $657.6 Million – – Second-Quarter GAAP Earnings per Share of $0.88 and Non-GAAP Earnings per Share of $1.63 – – Updates 2019 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-July 31, 2019-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter o

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (

Charles River Laboratories International, Inc. Form of Performance Share Unit granted under the 2018 Incentive Plan

Exhibit 4.1 FORM OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”) This Performance Share Unit Award (the “Award”) is granted as of February xx, 20xx by Charles River Laboratories International, Inc. (the “Company”) to «FN» «LN» (the “Participant”) on the terms and conditions as set forth in this Award Agreement and

Charles River Laboratories International, Inc. Form of Restricted Stock Unit granted under the 2018 Incentive Plan

Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this “Award Document”), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the “Plan”). Pursuant to Section 4(c) and Section 4(d) of the Pl

Charles River Laboratories International, Inc. Form of Non-Qualified Stock Option granted under the 2018 Incentive Plan

Exhibit 10.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Non-Qualified Stock Option Granted Under 2018 Incentive Plan The Company's most recent Annual Report to Shareholders containing the Company’s audited financial statements for the last three years and its Annual Report on Form 10-K is available on the Company's website at http://www.criver.com. You are urged to review those documents befor

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 29, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

CRL / Charles River Laboratories International, Inc. SD - - FORM SD

OMB APPROVAL OMB Number: 3235-0697 Expires: June 30, 2019 Estimated average burden hours per response….

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2019 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio

Charles River Laboratories Announces First-Quarter 2019 Results – First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share of $1.40 – – Reaffirms 2019 Guidance Including Citoxlab –

Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2019 Results – First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share of $1.40 – – Reaffirms 2019 Guidance Including Citoxlab – WILMINGTON, Mass.-(BUSINESS WIRE)-May 7, 2019-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the

Share Sale and Purchase Agreement dated April 27, 2019

Exhibit 2.1 SHARE SALE AND PURCHASE AGREEMENT between (1)AXA LBO FUND V SUPPLEMENTARY FPCI (2)JEAN FRANCOIS LE BIGOT (3)THE OTHER CTL SELLERS, as defined below (4)THE CANADIAN CTL SELLERS, as defined below (5)BLUE JAZZ SAS (6)BLUE TANGO SAS (together the “Sellers”) (7)CHARLES RIVER NEDERLAND B.V. (the “Purchaser”) (8)CHARLES RIVER LABORATORIES INTERNATIONAL, INC (the “Parent”) (9)CTL INTERNATIONAL

CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF CITOXLAB

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF CITOXLAB WILMINGTON, MA, April 29, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to customary closing adjustments

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2019 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Inco

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2019 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of inc

CRL / Charles River Laboratories International, Inc. DEF 14A

QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Exclusivity Agreement among CTL International SAS. (“CTL”) among Charles River Nederland B.V., Charles River Laboratories International, Inc. (as guarantor). AXO LBO Fund V Supplementary FPCI, Jean-Francios Le Bigot, Roy Foster, Patrick Spies, and certain other equity holders of CTI, dated as of February 12, 2019*

EX-2.2 Exhibit 2.2 Execution version AXA LBO FUND V SUPPLEMENTARY FPCI JEAN FRANCOIS LE BIGOT ROY FORSTER PATRICK SPIES BLUE JAZZ SAS BLUE TANGO SAS CTL INTERNATIONAL SAS CHARLES RIVER NEDERLAND B.V. EXCLUSIVITY AGREEMENT FEBRUARY 12, 2019 CONTENTS Articles Page 1.   Definitions 5 2.   Exclusivity 5 3.   Consultation of the employee representative bodies 7 4.   SPA Provisions 8 5.   Break-up fees

CHARLES RIVER LABORATORIES SIGNS BINDING OFFER TO ACQUIRE CITOXLAB – Further Strengthens Charles River’s Position as the Leading Global Early-Stage CRO – – Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.15 in 2019 and At Lea

EX-99.1 Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES SIGNS BINDING OFFER TO ACQUIRE CITOXLAB – Further Strengthens Charles River’s Position as the Leading Global Early-Stage CRO – – Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.15 in 2019 and At Least $0.35 in 2020 – WILMINGTON, MA, February 13, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) an

Regulation FD Disclosure

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2019 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction

Offer relating to CTL International SAS. (“CTL”) among Charles River Nederland B.V., Charles River Laboratories International, Inc. (as guarantor). AXO LBO Fund V Supplementary FPCI, Jean-Francios Le Bigot, Roy Foster, Patrick Spies, and certain other equity holders of CTI, dated February 12, 2019.*

EX-2.1 Exhibit 2.1 Execution version February 12, 2019 From: CHARLES RIVER NEDERLAND B.V., a Dutch Besloten Vennootschap, having its registered office located at Darwinweg 24, 2333CR Leiden (Netherlands) identified under number 000010497803, duly represented for the purpose hereof hereinafter, the Offeror With the participation of: CHARLES RIVER LABORATORIES INTERNATIONAL, INC., a Delaware corpora

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance – Fourth-Quarter Revenue of $601.5 Million and Full-Year Revenue of $2.27 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.21 and Non-GA

Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance – Fourth-Quarter Revenue of $601.5 Million and Full-Year Revenue of $2.27 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.21 and Non-GAAP Earnings per Share of $1.49 – – Full-Year GAAP Earnings per Share of $4.59 and Non-GAAP Earnings per Share of $6.03 – – Provides 2019

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 13, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp

CRL / Charles River Laboratories International, Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 29, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABO

Subsidiaries of Charles River Laboratories International, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Holdings LLC Delaware 5 Ballardvale C.V. Netherlands 6 Charles River Nederland B.V. Netherlands 7 Charles River Laboratories Holding SAS France 8 Charles Rive

CRL / Charles River Laboratories International, Inc. / VANGUARD GROUP INC Passive Investment

charlesriverlaboratoriesinte.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8 )* Name of issuer: Charles River Laboratories International Inc Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: Decemb

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2018 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo

Charles River Laboratories Announces Third-Quarter 2018 Results – Third-Quarter Revenue of $585.3 Million – – Third-Quarter GAAP Earnings per Share of $1.22 and Non-GAAP Earnings per Share of $1.53 – – Updates 2018 Guidance –

Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2018 Results – Third-Quarter Revenue of $585.3 Million – – Third-Quarter GAAP Earnings per Share of $1.22 and Non-GAAP Earnings per Share of $1.53 – – Updates 2018 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-November 7, 2018-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of

CRL / Charles River Laboratories International, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 29, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R

Consulting Agreement between Davide Molho and Charles River Laboratories, Inc. dated August 28, 2018

Exhibit 10.3 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the "Consulting Agreement"), made this 28th day of August, 2018 (the “Effective Date”), is entered into by Charles River Laboratories, Inc., with its principal place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (the "Company"), and Dr. Davide Molho (the "Consultant"). The Company desires to retain the services o

Separation Memorandum between Davide Molho and Charles River Laboratories, Inc. dated August 1, 2018 (revised on August 28, 2018)

Exhibit 10.1 CONFIDENTIAL To: Davide Molho From: Jim Foster Date: August 1, 2018 (Revised on August 28, 2018) Subject: Separation Agreement The purpose of this memorandum (“Memorandum”) is to formally advise you of a decision by Charles River Laboratories (the “Company”) to terminate your employment without cause and due to a position elimination pursuant to the terms of the 2010 Charles River Cor

Separation Agreement between Davide Molho and Charles River Laboratories, Inc. dated August 1, 2018 (revised on August 28, 2018)

Exhibit 10.2 Revised Date: August 28, 2018 Original Date: August 1, 2018 Personal and Confidential Dr. Davide A. Molho 56 W. Cedar Street Boston, MA 02114 Dear Davide: By this letter (“Letter Agreement”), we are offering to agree to the following arrangement with you concerning your separation from employment with Charles River Laboratories, Inc. (the “Company”). You have until August 28, 2018 to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2018 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 28, 2018 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction (Commi

Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations – Second-Quarter Revenue of $585.3 Million – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $1.62 – – Increases 2018 Rev

Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations – Second-Quarter Revenue of $585.3 Million – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $1.62 – – Increases 2018 Revenue Growth and Earnings per Share Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-August 8, 2018-Charles River Laboratories International,

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2018 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpora

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Charles River Laboratories International, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2018 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delawar

CRL / Charles River Laboratories International, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Financial Statements and Exhibits

8-K/A 1 dp920888ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2018 Commission File Number Exact Name of Registrant as Specified in Charter; State of Incorporation; Address and Telephon

ITEM 9.01 (b) UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 ITEM 9.01 (b) UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 3, 2018, Charles River Laboratories International, Inc. (“Charles River” or the “Company”), Forest Acquisition Corporation, a wholly-owned subsidiary of Charles River (“Merger Sub”), ACP Mountain Holdings, Inc. (“ACP”) and Avista Capital Partners IV GP, LP, in its capacity as Stockholder’s Representati

See Notes to Consolidated Financial Statements

Exhibit 99.1 ITEM 9.01 (a) FINANCIAL STATEMENTS OF BUSINESSES ACQUIRED ACP Mountain holdings, Inc. INDEPENDENT AUDITORS’ REPORT CONSOLIDATED FINANCIAL STATEMENTS: Consolidated Balance Sheet as of December 31, 2017 Consolidated Statement of Operations and Comprehensive Income for the Year ended December 31, 2017 Consolidated Statement of Changes in Shareholders’ Equity for the Year ended December 3

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2018 Commission File Number Exact Name of Registrant as Specified in Charter; State of Incorporation; Address and Telephone Number Former Name or Former Address, if Changed s

CRL / Charles River Laboratories International, Inc. FORM SD

OMB APPROVAL OMB Number: 3235-0697 Expires: June 30, 2019 Estimated average burden hours per response….

CRL / Charles River Laboratories International, Inc. FORM S-8

As filed with the Securities and Exchange Commission on May 18, 2018 Registration No.

Submission of Matters to a Vote of Security Holders

Charles River Laboratories International, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2018 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delaware 0

CRL / Charles River Laboratories International, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER

Charles River Laboratories International, Inc. 2018 Incentive Plan dated March 20, 2018

Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN Originally adopted by the Board of Directors On March 20, 2018 1.ADMINISTRATION Subject to the express provisions of the Plan, the Administrator has the authority to interpret the Plan; determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award; prescribe forms, rules a

Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations – First-Quarter Revenue of $494.0 Million – – First-Quarter GAAP Earnings per Share of $1.08 and Non-GAAP Earnings per Share of $1.38 – – Updates 2018 Guidance

Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations – First-Quarter Revenue of $494.0 Million – – First-Quarter GAAP Earnings per Share of $1.08 and Non-GAAP Earnings per Share of $1.38 – – Updates 2018 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-May 10, 2018-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results f

Current Report

8-K 1 a51804082.htm CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2018 Date of Report: (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) D

Form of Subordinated Debt Indenture between the Registrant and U.S. Bank National Association.

Exhibit 4.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK NATIONAL ASSOCIATION as Trustee Subordinated Indenture Dated as of , 20 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 8 Section 1.03. Incorporation by Reference of Trust Indenture Act 8 Section 1.04. Rules of Construction